| |||||||
|
|
Oxford, UK,
August
1st, 2006
- Oxford Gene Technology (OGT) is pleased to announce the conclusion
of a Japanese licensing agreement giving NGK Insulators Ltd. access to
OGT’s “Southern array patents”, the fundamental patents covering the
manufacture and marketing of oligonucleotide microarrays. NGK has also
been granted the rights to manufacture OEM microarrays for sale in
Japan. All NGK manufactured microarrays can by used by its customers
in a service
business.
Dr Michael Bennett, Vice President Licensing Asia, at OGT said: “OGT
have been working to successfully conclude license agreements with
several Japanese companies. The deal with NGK Insulators Ltd. involves
the purchase of OEM rights, the only Japanese microarray company to do
so.” - ENDS - For further information, please contact: At Oxford Gene Technology: Dr Michael Bennett, Vice President Licensing Asia
Oxford Gene
Technology
T:
+44 1865
842603 Media Enquiries: Annabel Entress, 0207 886 8150 / a.entress@northbankcommunications.com Sarah Jeffery, 0207 886 8150 / s.jeffery@northbankcommunications.com
Notes to editors
· OGT offers a comprehensive custom microarray consultancy service, from experimental design through all stages to data analysis and interpretation. It has a strong proven track record in providing custom microarray service in a range of applications, and recently announced the launch of its first microarray product, an Escherichia coli K12 ChIP on chip, the first ChIP microarray product to be launched as part of OGT’s Prokaryotic Chip2 family The key focus areas of OGT include: 1. Array-based application products and services for life science research and molecular diagnostics. OGT’s flexible and cost-effective, customised DNA microarray service covers a range of applications, offering specialist support and assisting customers with every aspect of their research, from initial consultation and experimental design to probe selection, array design and fabrication through to data analysis and interpretation 2. Development of innovative platform products for clinical research and diagnostics 3. Licensing. OGT operates an open licensing policy which has successfully provided access for a number of companies to OGT's fundamental intellectual property, particularly in the area of microarrays 4. Scientific collaborations to generate diagnostic biomarker intellectual property For further information on OGT visit http://www.ogt.co.uk/ - ENDS - |
|
| ||||||||